Dynacure to Present Preclinical Data on Disease Progression Modelling and ASO-Mediated Dynamin 2 Knockdown at World Muscle Society (WMS) Meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare.
Dynacure Recognizes Rare Disease Day 2021 biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. US 10, 865, 414 related to DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein (DNM2), for the treatment of Myotubular and Centronuclear Myopathies (CNM). The U.S. patent is part of a patent family, exclusively licensed from Ionis Pharmaceuticals, which covers modulators of DNM2 expression. This patent family includes one additional U.S. pending application and one European application and 18 other foreign pending applications (Australia, Brazil, Canada, Chili, China, Colombia, Israel, India, Japan, Korea, Mexico, Malaysia, New-Zealand, Peru, R
Share this article
Share this article
STRASBOURG, France and PHILADELPHIA, Jan. 21, 2021 /PRNewswire/ Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. Franchi to its Board of Directors. Ms. Franchi is an experienced board member, finance executive and operational leader with more than three decades of experience in the life sciences industry. I am very pleased to welcome Jean to the Dynacure Board, said Georges Gemayel, Chairman of the Board of Directors of Dynacure. Jean will be a valuable addition to our team, bringing expertise in financial and long-term strategies, and we look forward to her guidance.